JP2019533645A - 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ - Google Patents

標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ Download PDF

Info

Publication number
JP2019533645A
JP2019533645A JP2019514781A JP2019514781A JP2019533645A JP 2019533645 A JP2019533645 A JP 2019533645A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019533645 A JP2019533645 A JP 2019533645A
Authority
JP
Japan
Prior art keywords
ftn
protein
peg
agent
nanocage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533645A5 (https=
Inventor
シンル ファン，
シンル ファン，
ジュン ソ スク，
ジュン ソ スク，
ジャスティン ヘインズ，
ジャスティン ヘインズ，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2019533645A publication Critical patent/JP2019533645A/ja
Publication of JP2019533645A5 publication Critical patent/JP2019533645A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019514781A 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ Pending JP2019533645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395852P 2016-09-16 2016-09-16
US62/395,852 2016-09-16
PCT/US2017/052079 WO2018053434A1 (en) 2016-09-16 2017-09-18 Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Publications (2)

Publication Number Publication Date
JP2019533645A true JP2019533645A (ja) 2019-11-21
JP2019533645A5 JP2019533645A5 (https=) 2020-10-08

Family

ID=60002019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514781A Pending JP2019533645A (ja) 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ

Country Status (4)

Country Link
US (1) US11090391B2 (https=)
EP (1) EP3512563A1 (https=)
JP (1) JP2019533645A (https=)
WO (1) WO2018053434A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024228598A1 (ko) * 2023-05-04 2024-11-07 경북대학교 산학협력단 Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503704A (zh) * 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
WO2019222400A2 (en) * 2018-05-15 2019-11-21 Dnalite Therapeutics, Inc. Mucus-penetrating peptides, delivery vehicles and methods of therapy
EP3863610A4 (en) * 2018-10-10 2023-03-29 University of Washington High-polymer-density bioconjugate compositions and related methods
WO2020180144A1 (ko) * 2019-03-07 2020-09-10 경북대학교 산학협력단 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
JP7600993B2 (ja) * 2019-09-05 2024-12-17 味の素株式会社 ペプチド内包フェリチン
US20240150417A1 (en) * 2019-11-01 2024-05-09 Cellemedy Co.,Ltd Disease antigen-fused protein, and use thereof
EP4053153A4 (en) * 2019-11-01 2023-12-20 Cellemedy Co., Ltd PROTEIN FUSED WITH A MOLECULE CAPABLE OF BINDING AN IMMUNE CHECKPOINT MOLECULE AND USE THEREOF
JP7541390B2 (ja) * 2019-11-01 2024-08-28 セレメディー カンパニー，リミテッド 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
KR102658825B1 (ko) * 2020-10-23 2024-04-19 경북대학교 산학협력단 Pd-l1 결합 펩타이드 1을 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用
CN115160559B (zh) * 2021-04-02 2024-02-02 杭州宜生医药科技发展有限公司 一种peg化雷帕霉素化合物及其制备方法与应用
CN119326734B (zh) * 2024-12-17 2025-06-06 浙江大学 一种铁蛋白纳米颗粒及其药物递送系统的组装方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029947A1 (ja) * 2008-09-09 2010-03-18 国立大学法人京都大学 造影剤組成物及びその製造方法
JP2014518842A (ja) * 2011-02-25 2014-08-07 サウス ダコタ ステート ユニバーシティー ポリマーコンジュゲートタンパク質ミセル
JP2015505855A (ja) * 2011-12-14 2015-02-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
KR920003787B1 (ko) 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
WO2000011947A1 (en) 1998-08-28 2000-03-09 Uropath Pty. Ltd. Method of diagnosis of prostate cancer
DE60028361T2 (de) 1999-02-26 2007-05-10 Pacific Northwest Research Institute, Seattle Verfahren und zusammensetzungen zur karzinomdiagnose
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN101355965A (zh) 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
WO2007114946A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Acid-sensitive linkers for drug delivery
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
CA2921493A1 (en) 2012-08-21 2014-02-27 Brown University Ferritin-based tumor targeting agent, and imaging and treatment methods
US11202820B2 (en) * 2014-09-25 2021-12-21 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029947A1 (ja) * 2008-09-09 2010-03-18 国立大学法人京都大学 造影剤組成物及びその製造方法
JP2014518842A (ja) * 2011-02-25 2014-08-07 サウス ダコタ ステート ユニバーシティー ポリマーコンジュゲートタンパク質ミセル
JP2015505855A (ja) * 2011-12-14 2015-02-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM ENG J. (AUTHOR MANUSCRIPT), vol. 89, JPN6021015785, 2014, pages 33 - 41, ISSN: 0004637905 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 7, JPN6021015786, 2012, pages 1489 - 1509, ISSN: 0004637906 *
J NANOBIOTECHNOL., vol. Vol.13:73, JPN6021015787, 2015, pages 1 - 12, ISSN: 0004637907 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024228598A1 (ko) * 2023-05-04 2024-11-07 경북대학교 산학협력단 Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도

Also Published As

Publication number Publication date
US20190255189A1 (en) 2019-08-22
US11090391B2 (en) 2021-08-17
EP3512563A1 (en) 2019-07-24
WO2018053434A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
US11090391B2 (en) Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
Yang et al. Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy
Liu et al. Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment
Erel-Akbaba et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy
Huang et al. Protein nanocages that penetrate airway mucus and tumor tissue
Perche et al. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting
Han et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles
Yang et al. Application of coiled coil peptides in liposomal anticancer drug delivery using a zebrafish xenograft model
US11090367B2 (en) Restoration of tumor suppression using mRNA-based delivery system
JP2019218349A (ja) ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用
Wan et al. In vivo delivery of siRnas targeting EGFR and BRD4 expression by peptide-modified redox responsive PEG–PEI nanoparticles for the treatment of triple-negative breast cancer
JP2017512840A (ja) 癌治療のためのターゲティングされた重合ナノ粒子
Bhosale et al. Current perspectives on novel drug carrier systems and therapies for management of pancreatic cancer: An updated inclusive review
Ren et al. Peptide GE11–polyethylene glycol–polyethylenimine for targeted gene delivery in laryngeal cancer
AU2018379379B2 (en) Liposomal system for drug delivery
Ning et al. Targeted delivery of circPDHK1 siRNA via aptamer functionalized lipid nanoparticles inhibits ccRCC growth and migration
AU2019269590A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US20200390903A1 (en) Plectin-targeted liposomes/parp inhibitor in the treatment of cancer
Duan et al. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death
US20210077575A1 (en) Nanoparticles for the targeted delivery of therapeutic polypeptides
Sevieri Nanotechnological approaches for cancer diagnosis, treatment and management: implementation of Ferritin protein nanoparticles for tumor targeting
Lu et al. Biomimetic nanoparticles coated with ScFv-modified macrophage membranes for siRNA delivery to relieve brain metastases of lung cancer
CN121059833A (zh) 高渗透性氟化白蛋白双药纳米粒及其制备方法、协同化疗-免疫治疗系统与用途
Janani et al. Targeting the MUC1 tumor marker with an antibody improves the therapeutic efficacy of PEGylated liposomal doxorubicin in colon carcinoma.
Song et al. Engineered B. clausii extracellular vesicle-mediated homologous recombination impairment promotes the maintenance treatment efficacy of Olaparib in non-BRCA-mutated pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211112